Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01298011 · ClinicalTrials.gov registry record · Phase 2
Study of Gemcitabine and Abraxane to Treat Potentially Operable Pancreatic Cancer
A Phase 2 study, sponsored by Pancreatic Cancer Research Team.
- Completed
- Registry status
- Phase 2
- Development phase
- 25
- Enrollment target
NCT01298011 is a Phase 2 study that has completed, run by Pancreatic Cancer Research Team. The registered enrollment target is 25 participants.
The verdict
NCT01298011, a Phase 2 study, has completed, sponsored by Pancreatic Cancer Research Team.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 25 participants
- Enrollment target
Study Summary
The main purpose of this research study is to evaluate whether Abraxane and gemcitabine are effective in treating patients with operable pancreatic cancer.
Interventions
- DRUG Gemcitabine and Abraxane
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2011-05 |
| Est. Completion | 2015-05 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01298011
The ClinicalTrials.gov registry entry for NCT01298011 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 25 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pancreatic Cancer Research Team, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Gemcitabine and Abraxane is the first listed.
NCT01298011 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01298011 about?
NCT01298011 is a clinical study titled "Study of Gemcitabine and Abraxane to Treat Potentially Operable Pancreatic Cancer". The main purpose of this research study is to evaluate whether Abraxane and gemcitabine are effective in treating patients with operable pancreatic cancer.
What is the current status of trial NCT01298011?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 25 participants. The study started on 2011-05. Estimated completion is 2015-05.
What interventions are being tested in trial NCT01298011?
The interventions under investigation include: Gemcitabine and Abraxane (DRUG).
Who is sponsoring clinical trial NCT01298011?
This trial is sponsored by Pancreatic Cancer Research Team, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.